Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronocort vs Standard Glucocorticoid Therapy in Congenital Adrenal Hyperplasia
NCT02716818Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH) (2 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Change From Baseline to 24 Weeks of the Mean of the 24-hour Standard Deviation Score (SDS) Profile for 17-OHP. Started Feb 2016; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT02716818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716818.